Dong-A’s Stillen to be exposed to fiercer competition

Published: 2008-12-22 07:00:00

Updated: 2008-12-22 07:00:00

The homegrown drug in Korea will not be as stale as before with a growing number of pharmaceutical companies poising to enter a 70 billion Stillen market.

More than 20 pharmaceutical manufacturers are expected to release the first version of Stillen capsule, one of Dong-A’s flagship products ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK